This paper is only available as a PDF. To read, Please Download here.
Abstract
Objective
To assess predictive factors of primary stent patency in three groups of patients
with history of lower limb (LL) vein thrombosis: non-thrombotic iliac vein lesion
(NIVL), acute deep vein thrombosis (aDVT) and post thrombotic syndrome (PTS).
Methods
Consecutive patients with history of LL vein stenting from 7 hospitals were included
from January 2014 to December 2020. All patients received an iliac or common femoral
venous stent and had at least a 6-month follow-up available with stent imaging. The
anticoagulant and antiplatelet therapy strategies employed after venous stenting are
reported and compared between groups. This study included 377 patients: 134 NIVL,
55 aDVT and 188 PTS.
Results
Primary patency was significantly higher in the NIVL group (99.3%) compared to the
PTS group (68.6%) (p <.001) and the aDVT group (83.6%) (p=.002). PTS patients received
a significantly greater number of stents (p<.001) and had more stents below the inguinal
ligament (p<.001). Median follow-up was 28.8 months [IQR: 16; 47]. Discontinuation
of antiplatelet therapy at the last assessment was 83.6% for NIVL, 100% for aDVT and
95.7% for the PTS group (p<.001). Discontinuation of anticoagulation therapy at the
last assessment was 93.2% for NIVL, 25.0% for aDVT and 70.3% for the PTS group (p<.001).
The only predictor of worse primary patency in the aDVT group was long-term anticoagulation
before stenting.
Conclusion
Patients with NIVL have better primary patency after venous stenting than patients
with venous thrombotic disorders. Long-term anticoagulation before stenting was the
only factor associated with poorer primary patency in patient with aDVT.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Vascular and Endovascular SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
January 6,
2023
Received in revised form:
December 13,
2022
Received:
March 8,
2022
Publication stage
In Press Accepted ManuscriptIdentification
Copyright
© 2023 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.